EP
LPCN icon

Eversept Partners’s Lipocine LPCN Stock Holding History

Eversept Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Buy
+294,989
New +$2.57M 0.12% 84

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners's LPCN Position: Q1 2026 in Review

Eversept Partners opened a new position in Lipocine (LPCN) in Q1 2026: 294,989 shares worth $2.36M. The stake represents 0.12% of the portfolio and ranks #84 among its holdings.

47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Eversept Partners held 294,989 shares of Lipocine worth $2.36M as of Q1 2026.
  • Lipocine was a new Eversept Partners position in Q1 2026.
  • Lipocine made up 0.12% of Eversept Partners's portfolio in Q1 2026, its #84 holding.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.